Arcanobacterium

Jump to navigation Jump to search

WikiDoc Resources for Arcanobacterium

Articles

Most recent articles on Arcanobacterium

Most cited articles on Arcanobacterium

Review articles on Arcanobacterium

Articles on Arcanobacterium in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Arcanobacterium

Images of Arcanobacterium

Photos of Arcanobacterium

Podcasts & MP3s on Arcanobacterium

Videos on Arcanobacterium

Evidence Based Medicine

Cochrane Collaboration on Arcanobacterium

Bandolier on Arcanobacterium

TRIP on Arcanobacterium

Clinical Trials

Ongoing Trials on Arcanobacterium at Clinical Trials.gov

Trial results on Arcanobacterium

Clinical Trials on Arcanobacterium at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Arcanobacterium

NICE Guidance on Arcanobacterium

NHS PRODIGY Guidance

FDA on Arcanobacterium

CDC on Arcanobacterium

Books

Books on Arcanobacterium

News

Arcanobacterium in the news

Be alerted to news on Arcanobacterium

News trends on Arcanobacterium

Commentary

Blogs on Arcanobacterium

Definitions

Definitions of Arcanobacterium

Patient Resources / Community

Patient resources on Arcanobacterium

Discussion groups on Arcanobacterium

Patient Handouts on Arcanobacterium

Directions to Hospitals Treating Arcanobacterium

Risk calculators and risk factors for Arcanobacterium

Healthcare Provider Resources

Symptoms of Arcanobacterium

Causes & Risk Factors for Arcanobacterium

Diagnostic studies for Arcanobacterium

Treatment of Arcanobacterium

Continuing Medical Education (CME)

CME Programs on Arcanobacterium

International

Arcanobacterium en Espanol

Arcanobacterium en Francais

Business

Arcanobacterium in the Marketplace

Patents on Arcanobacterium

Experimental / Informatics

List of terms related to Arcanobacterium

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]

Synonyms and keywords: C. hemolyticum; Corynebacterium hemolyticum

Overview

Arcanobacterium haemolyticum initially named C. haemolyticum, was first described by MacClean et al. in 1946 from subjects suffering from sore throat. Controversies regarding classification were solved in 1982 when a new genus, Arcanobacterium (enigmatic bacterium) was created based on its peptidoglycan, fatty acid, and DNA characteristics, Since its initial description, the spectrum of diseases caused by A. haemolyticum has been expanded to include sepsis and osteomyelitis. Organisms are Gram-positive, facultative anaerobic, catalase negative rods (but transition to the coccal shape occurs as the organism grows) with arrangements described as matchbox or Chinese letters arrangements. Growth is enhanced in blood and by CO2. Hemolysis is detected on human blood agar plates, and routine plating of specimens suspected of containing A. haemolyticum on human blood agar is suggested to distinguish it from Streptococcus pyogenes (haemolytic on sheep blood). Pitting of the agar below the colonies also helps in identification. A. haemolyticum infection is most common in 15- to 25-year-old persons and manifests as exudative pharyngitis and/or tonsillitis accompanied by cervical lymphadenopathy.1,2 Symptoms look like those of ß-hemolytic streptococci or viral infection. A rash of the chest and of the abdomen, neck, or extremities is seen in 20% to 25% of cases enhancing the risk of diagnostic error as streptococcal infection or penicillin allergy, when ß-lactam therapy is initiated without exact diagnosis.[3] A. haemolyticum often occurs in polymicrobic infections together with typical respiratory pathogens such as streptococci. The isolation of classical pathogens from specimens that also contain A. haemolyticum might be in part responsible for the tendency to miss the organism. Little is known about the means by which A. haemolyticum causes infection or the associated skin manifestations. The organism is known to produce uncharacterized hemolytic agent(s), a neuraminidase and a phospholipase D (PLD) acting preferentially on sphingomyelin. PLD is known to result in tissue damage, but the role in disease of the cytotoxic effect caused by this extracellular toxin is not established. A. haemolyticum isolated from humans is susceptible to erythromycin (proposed as the first line drug ), clindamycin, gentamicin, and cephalosporins. The use of parenteral antimicrobial drugs must be limited to serious infections.[1]

Gallery

References

  1. "CDC".
  2. 2.0 2.1 2.2 "Public Health Image Library (PHIL)".

Template:Bacteria-stub